Volume 24, Number 12—December 2018
Research
Capnocytophaga canimorsus Capsular Serovar and Disease Severity, Helsinki Hospital District, Finland, 2000–2017
Estelle Hess1, Francesco Renzi1, Panu Karhunen1, Mélanie Dol, Adrien Lefèvre, Jenni Antikainen, Elodie Carlier, Johanna Hästbacka2, and Guy R. Cornelis2
Table 2
Patient demographics, clinical characteristics, and contact with dogs, Helsinki Hospital District, Finland, 2000–2017*
| Characteristic | No. patients† | Value |
|---|---|---|
| Age, y, median (IQR) |
73 |
55 (48.3–64.8) |
| Sex | 73 | |
| M | 38 (52.1) | |
| F |
35 (47.9) |
|
| Immune compromised | 73 | 7 (9.6) |
| Smoking | 48 | 30 (62.5) |
| Alcohol abuse |
49 |
18 (36.7) |
| Contact with dog | 73 | |
| Not known | 21 (28.8) | |
| Contact but not bitten | 15 (20.5) | |
| Bitten |
37 (50.7) |
|
| Disease severity | 70 | |
| Regular ward or emergency department | 45 (64.3) | |
| High surveillance unit | 11 (15.7) | |
| Intensive care unit |
14 (20.0) |
|
| Length of hospital stay, d, median (IQR) | 62 | 6 (3–13.3) |
| Deaths at day 30 | 73 | 3 (4.1) |
| Deaths at 1 y | 61 | 4 (6.6) |
| Amputation | 73 | 6 (8.2) |
*Values are no. (%) patients except as indicated. IQR, interquartile range.
†Because of missing data, number of patients in each category varied.
1These first authors contributed equally to this article.
2These authors were co–principal investigators.
Page created: November 19, 2018
Page updated: November 19, 2018
Page reviewed: November 19, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.